Outcome of Board Meeting (Appointment of Director)
Cadila Healthcare Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 13, 2016 has appointed Mr. Apurva S. Diwanji as an Additional Independent Director of the Company for a period of five years from May 13, 2016 till May 12, 2021, subject to approval of the members at the ensuing Annual General Meeting. The details of the terms of appointment are attached to this letter. Results Press Release for March 31, 2016
Cadila Healthcare Ltd has informed BSE about : 1. Result Press Release for the period ended March 31, 2016 Outcome of Board Meeting
Cadila Healthcare Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 13, 2016 has not recommended final dividend on the equity shares and the interim dividend declared on March 08, 216 is the final dividend on the equity shares of the Company for the financial Year ended on March 31, 2016. Announces Q4 & FY16 Results (Standalone & Consolidated), Form A (Standalone & Consolidated) & Auditors Report (Standalone & Consolidated) for the period ended March 31, 2016
Cadila Healthcare Ltd has announced the following results for the quarter & year ended March 31, 2016:The Audited Standalone results for the Quarter ended March 31, 2016The Company has posted a net profit of Rs. 3380 million for the quarter ended March 31, 2016 as compared to Rs. 3470 million for the quarter ended March 31, 2015. Total Income has increased from Rs. 14688 million for the quarter ended March 31, 2015 to Rs. 14876 million for the quarter ended March 31, 2016.... Post results conference call with investors / analysts
Cadila Healthcare Ltd has informed BSE regarding "Post results conference call with investors / analysts".
Zydus Cadila gets USFDA nod to sell generic diabetes drug
The group has received final approval from USFDA to market the drug in strengths of 1.25, 2.5 and 5 mg, Zydus Cadila said in a statement. Zydus receives final approval from the USFDA for Glyburide Tablets
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated May 11, 2016 titled "Zydus receives final approval from the USFDA for Glyburide Tablets". Sell Cadila Healthcare with a target of Rs 305: Mitesh Thacker
The stock was trading at Rs 415.80 at the time the analyst made the recommendation. The stock has been declining since the last week of April. Cadila Healthcare plans to raise Rs 18,500 cr
Zydus Cadila group firm Cadila Healthcare today said it is planning to raise up to Rs 18,500 crore through issuance of shares and various other securities. The board of directors at its meeting to ...